Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links

Bibliography

• BROWNLEE M: Glycation and diabetic complications. Diabetes (1994) 43: 836–841.
   PubMed Web of Science ®Google Scholar
• BUCALA R, CERAMI A: Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv. Pharm. (1992) 23:1–33.
   PubMedGoogle Scholar
• SINGH R, BARDEN A, MORI T, BEILIN L: Advanced glycation end-products: a review. Diabetologia (2001) 44:129–146.
   PubMed Web of Science ®Google Scholar
• •This is an excellent review on advanced glycosylation, consequences and possible therapeutic approaches.
   Google Scholar
• BROWNLEE M: The pathological implications of protein glycation. Chit. Invest. Med. (1995) 18:275–281.
   Web of Science ®Google Scholar
• CERAMI A, ULRICH P: Pharmaceutical intervention of advanced glycation endproducts. Ageing vulnerability:causes and intervention. Novartis Found. Symp. (2001) 235:202–216.
   PubMedGoogle Scholar
• AL-ABED Y, KAPURNIOTU A, BUCALAR: Advanced glycation end products: detection and reversal. Meth. Enz. (1999) 309:152–172.
   PubMed Web of Science ®Google Scholar
• SHAW SM, CRABBE JC: Monitoring theprogress of non-enzymatic glycation in vitro. Int. J. Peptides Protein Res. (1994) 44:594–602.
   PubMedGoogle Scholar
• IKEDA K, NAGAI R, SAKAMOTO T et al:Immunochemical approaches to AGE-structures: characterization of anti-AGE-antibodies. j Immunol Methods (1998) 215:95–104.
   PubMed Web of Science ®Google Scholar
• SAJITHAL GB, CHITRA E CHANDRAKASAN G: Advanced glycation end products induce crosslinking of collagen in vitro. Biochim. Biophys. Acta (1998) 1407:215–224.
   PubMed Web of Science ®Google Scholar
• FU M-X, WELLS-KNECHT KJ, BLACKLEDGE JA et al: Glycation, glycoxidation and crosslinking of collagen by glucose. kinetics, mechanism and inhibition of late stages of maillard reaction. Diabetes (1994) 43:676–683.
   Google Scholar
• LUTHRA M, BALASUBRAMANIAN D: Nonenzymatic glycation alters protein structure and stability: a study of two lens crystallins. Bid. Chem. (1993) 268:18119–18127.
   Web of Science ®Google Scholar
• KOCHAKIAN M, MANJULA BN, EGAN JJ: Chronic dosing with aminoguanidine and novel advanced glycosylation end products-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes (1996) 45:1694–1700.
   PubMed Web of Science ®Google Scholar
• FRYE EB, DEGENHARDT TP THORPE S, BAYNES JW: Role of maillard reaction in aging of tissue proteins. Advanced glycation end product-dependant increase in Imidazolium cross-links in human lens proteins J Bia. Chem. (1998) 273: 18714–18719.
   Google Scholar
• LO TWC, WESTWOOD ME, MCLELLAN AC et al.: Binding and modification of proteins by methylglyoxal underphysiological vonditions. j. Biol. Chem. (1994) 269:32299–32305.
   PubMed Web of Science ®Google Scholar
• DEGENHARDT TI THORPE SR, BAYNES JW: Chemical modification of proteins by methylglyoxal. Cell. Ma Biol. (1998) 44:1139–1145.
   Web of Science ®Google Scholar
• SHIPANOVA IN, GLOMB MA, NAGARAJ RH: Protein modification by methyl glyoxal: Chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. Biochem. Biophys. (1997) 344:29–36.
   PubMed Web of Science ®Google Scholar
• UCHIDA K, KHOR OT, OYA T et al.: Protein modification by a Maillad reaction intermediate methylglyoxal. Immunochemical detection of fluorescent 5-methyllimidazolone derivatives in vivo. FEBS Lett. (1998) 410:313–318.
   Google Scholar
• SKOVSTED IC, CHRISTENSEN M, BREINHOLT J, MORTENSEN SB: Characterization of a novel AGE-compound derived from lysine and 3- deoxyglucosone. Cell. Mol. Biol. (1998) 44:1159–1163.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA H, MITSUHASHI T, KUWAJIMA S etal.: Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rats. Diabetes (1993) 42:345–350.
   Google Scholar
• LUBEC B, WENINGER M, POP OW C et al.: In vivo monitoring of serum protein crosslinking in patients with diabetes mellitus. Evidence for pharmacological modification of immunoglobulin G crosslinks. Amino Acids (1993) 4:111–119.
   Google Scholar
• MAKITA Z, VLASSARA H, CERAMI A, BUCALA R: Immunochemical detection of advanced glycosylation end products in vivo. j Biol. Chem. (1992) 267:5133–5138.
   PubMed Web of Science ®Google Scholar
• MITSUHASHI T, NAKAYAMA H, ITOH T et al.: Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. (1993) Diabetes 42:826–832.
   Google Scholar
• YANAGISAWA K, MAKITA Z, SHIROSHITA K et al.: Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism (1998) 47:1348–1353.
   PubMed Web of Science ®Google Scholar
• KUWAJIMA S: Immunochemical determination of advanced glycation end products in erythrocyte peripheral-membrane proteins from diabetic patients. Hokkadio J Med. Sci. (1993) 68:695–704.
   PubMedGoogle Scholar
• ANDO K, BEPPU M, KIKUGAWA K. et al.: Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in circulation. Biochim. Biophys. Res. Comm. (1999) 258:123–127.
   Google Scholar
• BROWNLEE M: Glycation products and the pathogenesis of diabetic complications. Diabetes Care (1992) 15:1835–1842.
   PubMed Web of Science ®Google Scholar
• RUDERMAN NB, WILLIAMSON JR, BROWNLEE M: Glucose and diabetic vascular disease. FASEB J(1992) 6:2905–2914.
   PubMed Web of Science ®Google Scholar
• KROLEWSKI M, EGGERS PW, WARRAM JH: Magniude of end-stage renal disease in IDDM: a 35 year follow - up study. Kidney mt. (1996) 50:2041–2046.
   PubMed Web of Science ®Google Scholar
• MAKITA Z, RADOFF S, RAYFIED EJ et al.: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl. Med. (1991) 325: 836–842.
   PubMed Web of Science ®Google Scholar
• RAJ DSC, CHOUDHURY D, WELBOURNE TC, LEVI M: Advanced glycation end products: a nephrologist's perspective. Am. I Kidney Dis. (2000) 35:365–380.
   PubMed Web of Science ®Google Scholar
• MAKINO H, SHIKATA K, HIRONAKA K et al.: Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int. (1995) 48:517–526.
   PubMed Web of Science ®Google Scholar
• VLASSARA H, STRIKER LJ, TEICHBERG S et al.: Advanced glycation end products induce glomerulosclerosis and albuminuria in normal rats, Proc. Natl. Acad. Sci. USA (1994) 91: 11704–11708,
   PubMed Web of Science ®Google Scholar
• YAMADA K, MIYAHARA Y, HAMAGUCHI K et al.: Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure. Clic]. Nephrol. (1994) 42:354–361.
   PubMed Web of Science ®Google Scholar
• NISHINO T, HORT Y, SHIIKI H et al.: Immunochemical detection of advanced glycosylation end products within vascular lesions and glomerulii in diabetic nephropathy. Human Pathol . (1995) 26:308–313.
   PubMed Web of Science ®Google Scholar
• MAKITA Z, BUCALA R, RAYFIELD EJ et al.: Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet (1994) 343:1519–1522.
   PubMed Web of Science ®Google Scholar
• SOULIS-LIPAROTA T, COOPER M, PAPAZOGLOU D et al.: Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes (1991) 40:1328–1344.
   PubMed Web of Science ®Google Scholar
• CHO HK, KOZU H, PEYMAN GA, PARRY GJ, KHOOBEHI B: The effect of aminoguanidine on the blood-retinal barrier in streptozotocin-induced diabetic rats. Ophthal. Surg. (1991) 22: 44–47.
   PubMedGoogle Scholar
• HAMMES H-P, MARTIN S, FEDERLIN K, GEISEN K, BROWNLEE M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Nati Acad. Li. USA (1991) 88:11555–11558.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, IKEDA K, HORIUCHI S, ZHAO H, ABRAHAM EC: Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lens. Biochem. Biophys. Res. Comm. (1997) 241:352–354.
   PubMed Web of Science ®Google Scholar
• LYONS TJ, SILVESTRI G, DUNN JA, DYER DG, BAYNES JW : Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes (1991) 40:1010–1015.
   PubMed Web of Science ®Google Scholar
• LI JJ, SURINI M, CATSICAS S, KAWASHIMA E, BOURAS C: Age-dependant accumulation of advanced glycosylation end products in human Neurons Neurobiol. Aging (1995) 16:69–76.
   Google Scholar
• CAMERON NE, COTTER MA, DINES K, LOVE A: Effects of aminoguanidine on peripheral function and polyol pathway metabolites in STZ-diabetic rats. Diabetologia (1992) 35:946–950.
   PubMed Web of Science ®Google Scholar
• MONNIER VM, MIYATA S, SELL DR: Relevance of early and advanced Maillard reaction in diabetic neuropathy. Diabetes. Med. (1993) 10\(Suppl. 2):103S–106S.
   Google Scholar
• ZIMMERMAN GA, MEISTRELL III M, BLOOM 0 et al.: Neurotoxicity of advanced glycation end products during focal stroke and neuroprotective effect of aminoguanidine. Proc. Nail. Acad. St". USA (1995) 92:3744–3748.
   Google Scholar
• COCKROFT KM, MEISTRELL III M, ZIMMERMAN GA et al.: Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke (1996) 27:1393–1398.
   PubMed Web of Science ®Google Scholar
• GERSTEIN HC: Glucose - a continuous risk factor for cardiovascular disease. Diabetes Med. (1997) 14:S25–S31.
   PubMed Web of Science ®Google Scholar
• LAKATTA EG: Cardiovascular regulatory mechanisms in advanced age. Physiol. Rev (1993) 73:413–467.
   PubMed Web of Science ®Google Scholar
• SIMS TJ, RASMUSSEN LM, OXLUND H, BAILEY AJ: The role of glycation crosslinks in diabetic vascular stiffening. Diabetologia (1996) 39:946–951.
   PubMed Web of Science ®Google Scholar
• AVENDANO GF, AGARWAL RK, BASHEY RI et al.: Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes (1999) 48:1443–1447.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M, VLASSARA H, KOONEY A etal.: Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science (1983) 232:1629–1632.
   Google Scholar
• BUCALA R, MAKITA Z, KOSCHINSKY T et al.: Lipid advanced glycosylation. pathway for lipid oxidation in vivo. Proc. Natl .Acad. Li. USA (1993) 90:6434–6438.
   PubMed Web of Science ®Google Scholar
• VLASSARA H: Advanced glycosylation end products and athersclerosis. Ann. Med. (1996) 28:419–428.
   PubMed Web of Science ®Google Scholar
• IMANAGA Y, SAKATA N, TAKEBAYASHI S etal.: In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human athersclerotic plaques. Atherosclerosis (2000) 150:343–355.
   Google Scholar
• BUCALA R, MAKITA Z, VEGA G et al.: Modification of low density lipoproteins by advanced glycosylation end products contributes to dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Li. USA (1994) 91:9441–9445.
   PubMed Web of Science ®Google Scholar
• OHGAMI N, NAGAI R, IKEMOTO M et al.: CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products. J. Biol. Chem. (2001) 276: 3195–3202.
   PubMed Web of Science ®Google Scholar
• PANAGIOTOPOULOS S, O'BRIEN R, BUCALA R et al.: Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbits. Atherosclerosis (1998) 136:125–131.
   Google Scholar
• TAKEDA A, YASUDA T, MIYATA T et al.:Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci. Lett. (1996) 221:17–20.
   PubMed Web of Science ®Google Scholar
• SASAKI N, FUKATSU R, TSUZUKI K et al.: Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Path. (1998) 153:1149–1155.
   PubMed Web of Science ®Google Scholar
• CASTELLANI RJ, HARRIS PLR, SAYRE LM et al.: Active glycation in neurofibrillary pathology of Alzheimer's disease: ne-(Carboxymethyfilysine and hexitol-lysine. Free Rad. Biol. Med. (2001) 31:175–180.
   PubMed Web of Science ®Google Scholar
• ELLIS EN, GOOD BH: Prevention of Glomerular basement membrane thickening by aminoguanidine in experimental diabetes. Metabolism (1991) 40:1016–1019.
   PubMed Web of Science ®Google Scholar
• •Describes the results of randomised Phase III clinical trial of pimagedine indicating the beneficial effects on nephropathy and retinopathy.
   Google Scholar
• EDELSTEIN D, BROWNLEE M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia (1992) 35:96–97.
   PubMed Web of Science ®Google Scholar
• SOULIS T, COOPER M, VRANES D, BUCALA R, JERMUS G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. (1996) 50:627–634.
   PubMed Web of Science ®Google Scholar
• IHKANDAR SS, PATRICK JD, CASE LD: Protective effect of aminoguanidine against glomerulosclerosis in spontaneous diabetic mice. FASEB J. (1991) 4:A1227
   Google Scholar
• YAGIHASHI S, KAMIJO M, BABA M et al.: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of streptozotocin-diabetic rats. Diabetes (1992) 41:47–52.
   PubMed Web of Science ®Google Scholar
• KIHARA M, SCHMELZER J, PODOUSLO J et al.: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology and oxygen free radicals. Proc. Nat. Acad. Li. USA (1991) 88:6107–6111.
   PubMed Web of Science ®Google Scholar
• CORMAN B, DURIEZ M, POITEVIN P et al.: Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc. Nati Acad. Sci. USA (1998) 95:1301–1306.
   PubMed Web of Science ®Google Scholar
• HUIJBERTS MSP, WOLFFENBUTTEL BHR, STRUIJKER BOUDIER SHAJ et al.: Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J. Clin. Invest. (1993) 92:1407–1411.
   Google Scholar
• NORTON GR, CANDY G, WOODWISS AJ: Aminoguanidine prevents decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation (1996) 93: 1905–1912.
   PubMed Web of Science ®Google Scholar
• BOLTON WK, CATTRAN DC, WILLIAMS ME etal.: Randomized trial of an inhibitor of advanced glycosylation end product formation in patients with diabetic nephropathy. (2001) Manuscript in preparation
   Google Scholar
• APPEL G, BOLTON K, FREEDMAN B et al.: Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of diabetic nephropathy in patients with Type 1 Diabetes Mellitus (DM) Am. Soc. Nephrol. (1999). Abstract.
   Google Scholar
• RASKIN P, CATTRAN D, WILLIAMS M et al.: Pimagedine (PG) reduces progression of retinopathy and lowers lipid levels in patients with Type 1 diabetes mellitus (DM). Am. Soc. Nephrol. (1999). Abstract.
   Google Scholar
• WHITTIER F, SPINOWITZ B,WUERTH J-P,CARTWRIGHT K: Pimagedine (PG) safety profile in patients with Type 1 Diabetes Mellitus (DM). Am. Soc. Nephrol. (1999). Abstract.
   Google Scholar
• CORBETT JA, TILTON RG, CHANG Ket al.: Aminoguanidine, a Novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes (1992) 14:552–556.
   Google Scholar
• KOMERS R, ALLEN T, COOPER ME: Role of Endothelium-Derived Nitric Oxide in the pathogenesis of renal hemodynamic changes of experimental diabetes. Diabetes (1994) 43: 1190–1197.
   PubMed Web of Science ®Google Scholar
• SOULIS T, SASTRA S, THALLAS V et al.:Relative contributions of advanced glycation and nitric oxide synthase inhibition to amino-guanidine mediated renoprotection in diabetic rats. Diabetologia (1997) 40:1141–1151.
   PubMed Web of Science ®Google Scholar
• NILSSON BO: Biochemical effects of aminoguanidine:an update. Inflammation Research (1999) 48:509–515.
   PubMed Web of Science ®Google Scholar
• MALLON VM, ULRICH P, BOYD TA et al.: N42-(4-morpholino)ethyll-N'-aminoguanidine (MEAG) inhibits AGE.-formation in vitro and diabetic changes in STZ-diabetic rats without inhibiting diamine oxidase(DA0) ornitric oxide synthase (NOS). Diabetes (1993) 42\(Suppl. 1):106A.
   Google Scholar
• FORBES JM, SOULIS T, THALLAS V et al.: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia (2001) 44:108–114.
   PubMed Web of Science ®Google Scholar
• RAHBAR S, YERNENI la, SCOTT S, GONZALES N, LALEZARI I: Novel inhibitors of advanced glycation end products. Mol. Cell Biol. Res. Comm. (2000) 3:360–366.
   PubMedGoogle Scholar
• WADA R, NISHIZAWA Y, YAGIHASHI N et al.: Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur.Inverst. (2001) 31:513–520.
   PubMed Web of Science ®Google Scholar
• KHALIFAH RG, BAYNES JW, HUDSON BG: Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochim. Biophys. Res. Comm. (1999) 257:251–258.
   PubMed Web of Science ®Google Scholar
• •This review describes the possible steps in AGE-pathway to target the design of inhibitors and focuses on 'Amadorins' a novel class of post-Amadori inhibitors.
   Google Scholar
• BOOTH AA, KHALIFAH RG, HUDSON BG: Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end products: comparison with aminoguanidine. Biochim. Biophys. Res. Comm. (1996) 220:113–119.
   Google Scholar
• KHALIFAH RG, BOOTH AA, GATTONE VH,VAN DEN BORN J: Effects of pyridoxamine, a novel post-amadori AGE-inhibitor on nephropathy induced by glycated albumin. j Am. Soc. Nephrof 30th Ann. Meeting (1997) A2988. NEED PLACE OF MEETING
   Google Scholar
• ALDERSON NL, METZ TO, CHACHICH ME et al.: An AGE.--inhibitor, pyridoxamine(PM) is more effective than anti-oxidants or Enalapril (EP) in preventing nephropathy in STZ-diabetic rats. 61st Scientific Sessions J Am. Blab. Ass (2001) 696P. Abstract.
   Google Scholar
• VASAN S, ZHANG X, ZHANG X A et al.:An agent cleaving glucose-derived protein crosslinks in vitro and In vivo. Nature (1996) 382:275–278
   Google Scholar
• •Provides the proof of concept for crosslink breakers.
   Google Scholar
• COOPER ME. THALLAS V, FORBES J etal.: The crosslink breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end product accumulation. Diabetologia (2000) 43: 660–664.
   Google Scholar
• THORNALLEY PJ, MINI-LAS HS: RapidHydrolysis and slow a43 -dicarbonyl cleavage of an agent proposed to cleave glucose-Derived Protein Cross-links. Biochem. Pharmacol. (1999) 57:303–307.
   PubMed Web of Science ®Google Scholar
• VARAGIC J, SUSIC D, FROHLICH ED: Cardiovascular effects of an advanced glycation end product breaker ALT-i11n adult spontaneously hypertensive rats. Amer. Coll. Cardiol. 50th Annual Scientific Session (2001). Session 1506.
   Google Scholar
• ASIF M, EGAN J, VASAN S et al.: An advanced glycation end product cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Nati Acad. Sci. USA (2000) 97: 2809–2813.
   PubMed Web of Science ®Google Scholar
• VAITKEVICIUS PV, LANE M, SPURGEON H et al.: A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Li. USA (2001) 98: 1171–1175.
   PubMed Web of Science ®Google Scholar
• WOLFFENBUTTEL BHR, BOULANGER CM, CRIJNS FRL et al.: Breakers of advanced glycation end products restore large artery properties in experimenal diabetes. Proc. Natl. Acad. Sci. USA (1998) 95:4630–4634.
   PubMed Web of Science ®Google Scholar
• KASS DA, SHAPIRO EP, KAWAGUCHI M et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation (2001) 104:r8–r18.
   Web of Science ®Google Scholar
• ••This paper describes the Phase II clinicaltrial of ALT-711 and the improvement in arterial compliance achieved in older individuals with stiffened vasculature. The results indicate the therapeutic potential of ALT–711.
   Google Scholar
• LO TWC, SELWOOD T, THORNALLEY PJ: The reaction of methylglyoxal with aminogunanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem. Pharmacol. (1994) 48:1865–1870.
   PubMed Web of Science ®Google Scholar
• EDELSTEIN D, BROWNLEE M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes (1992) 41:26–29.
   PubMed Web of Science ®Google Scholar
• KHATAMI M, SULDAN Z, DAVID I, ROCKEY JH: Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on non-enzymatic glycosylation. Life Sci. (1988) 43:1725–1731.
   PubMed Web of Science ®Google Scholar